Zoladex

NEW YORK (Reuters) - Interest in Dendreon Corp's Provenge vaccine to treat prostate cancer seems to be waning following recent approval of Johnson & Johnson's more-convenient and faster-acting Zytiga treatment, according to some doctors and industry analysts.

NEW YORK (Reuters Health) - Older men who opt for hormone-blocking therapy to treat prostate cancer might be slightly raising their risk of developing cataracts, hints new research.

NEW YORK (Reuters Health) - Men who opt for hormone-blocking therapy to treat prostate cancer may be increasing their risk of developing colon cancer, hints a study published this week in the Journal of the National Cancer Institute.

NEW YORK (Reuters Health) - Men who opt for hormone-blocking therapy to treat prostate cancer may be increasing their risk of developing colon cancer, hints a study published this week in the Journal of the National Cancer Institute.

Pharmaceutical company AstraZeneca on Thursday reported a 27 percent drop in third-quarter profit as it set aside nearly half a billion dollars to settle claims that its anti-psychotic drug Seroquel has harmful side-effects.

WASHINGTON (Reuters) - Hormone treatments for prostate cancer need new warnings about a small increased risk of diabetes and heart problems including sudden death, U.S. health officials said on Wednesday.

WASHINGTON (Reuters) - The U.S. Food and Drug Administration is examining if certain hormone treatments for men with prostate cancer pose a greater risk of diabetes or heart problems than other therapies.

The Food and Drug Administration is looking into data suggesting a group of prostate cancer drugs increase the risk of diabetes and heart disease.

FDA warns that early evidence shows links between prostate cancer drugs and diabetes. The Food and Drug Administration is looking into data suggesting a group of prostate cancer drugs increase the risk of diabetes and heart disease.

AstraZeneca loses appeal over drug wholesale price inflation lawsuit in Massachusetts. An appeals court on Wednesday upheld a lower court's ruling that AstraZeneca inflated the price of expensive drugs in Massachusetts.